Cover Image
Market Research Report

Methionine Aminopeptidase 2 - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 364842
Published Content info 62 Pages
Delivery time: 1-2 business days
Price
Back to Top
Methionine Aminopeptidase 2 - Pipeline Review, H2 2019
Published: December 27, 2019 Content info: 62 Pages
Description

Summary

According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 11 molecules.

Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.

The report 'Methionine Aminopeptidase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Gastrointestinal, Genetic Disorders and Infectious Disease which include indications Obesity, Non-Alcoholic Steatohepatitis (NASH), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Solid Tumor, Giardiasis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Prader-Willi Syndrome (PWS) and Type 2 Diabetes.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
  • The report reviews Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2055TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
  • Asieris Pharmaceuticals Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Merck KGaA
  • Primetime Life Sciences LLC
  • SynDevRx Inc
  • Takeda Pharmaceutical Co Ltd
  • Zafgen Inc
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
  • APL-1301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • beloranib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fumagillin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-8891 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitroxoline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLS-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDX-7195 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDX-7320 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZGN-1061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZGN-1345 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
  • Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 24, 2019: Zafgen announces agreement With U.S. Food And Drug Administration on new nonclinical study design for ZGN-1061
  • Jun 26, 2019: Asieris concludes enrolment for Phase Ib trial of APL-1202
  • Jun 10, 2019: Zafgen presented full results of Phase 2 clinical trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
  • May 30, 2019: Zafgen announces regulatory update on ZGN-1061
  • Jan 17, 2019: Zafgen announces positive results for second cohort of phase 2 clinical trial of ZGN-1061
  • Nov 26, 2018: Zafgen provides update on investigational new drug application for ZGN-1061
  • Nov 01, 2018: Asieris announced appointment of Dr. Gail Brown as acting Chief Medical Officer
  • Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
  • Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
  • May 30, 2018: Asieris Awarded Best Poster at AUA 2018 Annual Meeting
  • Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
  • Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
  • Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
  • Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
  • Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Pipeline by Merck KGaA, H2 2019
  • Pipeline by Primetime Life Sciences LLC, H2 2019
  • Pipeline by SynDevRx Inc, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Zafgen Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top